Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06441474 · ClinicalTrials.gov registry record · NA
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women
A NA study of Breast Cancer Female, sponsored by University of Colorado, Denver.
- Active
- Registry status
- NA
- Development phase
- 750
- Enrollment target
- 2
- Study locations
NCT06441474: Active NA study of Breast Cancer Female, sponsored by University of Colorado, Denver.
NCT06441474 is a NA study of Breast Cancer Female that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 750 participants, above the 676-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (11% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06441474, a NA study of Breast Cancer Female, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
- 2
- Study locations
Study Summary
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
Primary Outcome
Participants are asked whether they agree or disagree with their Gail Model risk estimate. An open text box allows them to write the risk number that they believe is accurate for them.
Conditions Studied
Interventions
- BEHAVIORAL Presentation of personal breast cancer risk estimate
Study Locations (2)
Colorado
- University of Colorado Denver - Aurora
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2028-04-02 |
| Phase | NA |
What the registry record for NCT06441474 still lists
NCT06441474 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 676-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Presentation of personal breast cancer risk estimate is the first listed.
NCT06441474 reports a single indexed study location in Colorado, Missouri.
Frequently Asked Questions
What is clinical trial NCT06441474 about?
NCT06441474 is a clinical study titled "Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women". The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
What is the current status of trial NCT06441474?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2025-04-02. Estimated completion is 2028-04-02.
What conditions does trial NCT06441474 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT06441474?
The interventions under investigation include: Presentation of personal breast cancer risk estimate (BEHAVIORAL).
Who is sponsoring clinical trial NCT06441474?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06441474 being conducted?
This trial has 2 study locations across Colorado, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06441474's enrollment target sits among peer trials
750 6th of 46 higher than 41 of 46 other Breast Cancer Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Breast Cancer Resiliency Through Exercise Program (B-REP)
RECRUITING · NA
-
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Cognitive Rehabilitation Following Breast Cancer Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI